Document is current
Any future updates will be listed below
-
Authors
Arendse, Regan https://orcid.org/0000-0003-3398-8476
Rahman, Proton
Baer, Philip
Haaland, Derek
Bessette, Louis https://orcid.org/0000-0002-6834-2731
Sholter, Dalton https://orcid.org/0009-0005-4740-6811
Rachich, Meagan
Rampakakis, Emmanouil https://orcid.org/0000-0002-7427-8246
Marrache, Anne Marilise
Lehman, Allen J. https://orcid.org/0000-0003-2315-7919
Asin-Milan, Odalis
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00741793 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry (Results)
https://doi.org/10.1136/bmjopen-2019-036245
Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
https://doi.org/10.1007/s40744-025-00788-0
Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry
https://doi.org/10.1136/bmjopen-2017-016619
-
Funding
Funding for this research was provided by:
Johnson and Johnson
- License Information
-
More Information
Article History
Received: 1 May 2025
Accepted: 18 July 2025
First Online: 19 September 2025
Declarations
:
: Regan Arendse has not declared any conflicts of interest relevant to this study; Proton Rahman has received consulting fees from Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Novartis, and Pfizer, and has also received research grants from Johnson & Johnson and Novartis; Philip Baer has received consulting fees from AbbVie, Amgen, AstraZeneca, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, GlaxoSmithKline, Innomar, JAMP Pharma, Johnson & Johnson, McKesson, Novartis, Opticann, Organon, Pfizer, Teva, and Viatris; Derek Haaland has received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi Genzyme, Takeda, and UCB; Louis Bessette reports speaker’s bureau for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Johnson & Johnson, MSD, Novartis, Organon, Pfizer, Sandoz, Sanofi, Teva, and UCB; consulting for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Gilead, Johnson & Johnson, MSD, Novartis, Organon, Pfizer, Sandoz, Sanofi, Teva, and UCB; grant/research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Sanofi, and UCB. Dalton Sholter has not declared any conflicts of interest relevant to this study; Meagan Rachich and Odalis Asin-Milan are employees of Johnson & Johnson; Anne Marilise Marrache and Allen J Lehman are former employees of Johnson & Johnson; this work was done while they were employees; Anne Marilise Marrache is a current employee of Lundbeck Canada Inc; Allen J Lehman is a current employee of Novartis; Emmanouil Rampakakis is an employee of JSS Medical Research and is a paid consultant of Johnson & Johnson.
: The BioTRAC study was conducted in accordance with the Declaration of Helsinki. Ethics approval was obtained from a central Research Ethics Board (REB) IRB Service, Ontario, Canada now known as Advarra, for private practices and from respective REBs for institutional sites: Sunnybrook Health Sciences Centre REB, Winnipeg Clinical Ethics Committee, Mount Sinai Hospital REB, University of British Columbia REB, CHUS Centre de Recherche, Health Research Ethics Board of Alberta, Horizon Health Network REB, and Hôpital Maisonneuve-Rosemont. Prior to enrolment, patients were required to provide written informed consent to participate.
